This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKYA Akoya Biosciences (AKYA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Akoya Biosciences Stock (NASDAQ:AKYA) Get Akoya Biosciences alerts:Sign Up Key Stats Today's Range$1.29▼$1.2950-Day Range$1.12▼$1.3752-Week Range$0.93▼$1.64VolumeN/AAverage Volume657,305 shsMarket Capitalization$64.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Read More Receive AKYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKYA Stock News HeadlinesAKYA Akoya Biosciences, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comAKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAJune 20, 2025 | prnewswire.comNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 8 at 1:00 AM | Porter & Company (Ad)Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative ProposalMay 23, 2025 | prnewswire.comAkoya surges as unsolicited buyout offer risks Quanterix mergerMay 21, 2025 | msn.comAkoya Biosciences Reports First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comAKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAMay 7, 2025 | businesswire.comAkoya Unveils ADC Breast Cancer Assay, Validates IO60 Spatial Panel At AACR 2025April 26, 2025 | nasdaq.comSee More Headlines AKYA Stock Analysis - Frequently Asked Questions How were Akoya Biosciences' earnings last quarter? Akoya Biosciences, Inc. (NASDAQ:AKYA) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.03. The company earned $16.64 million during the quarter, compared to analysts' expectations of $20.19 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 487.85% and a negative net margin of 59.44%. When did Akoya Biosciences IPO? Akoya Biosciences (AKYA) raised $125 million in an IPO on Friday, April 16th 2021. The company issued 6,580,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO. What other stocks do shareholders of Akoya Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akoya Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/12/2025Today6/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:AKYA CIK1711933 Webwww.akoyabio.com Phone855-896-8401FaxN/AEmployees90Year Founded2015Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.37 million Net Margins-59.44% Pretax Margin-59.28% Return on Equity-487.85% Return on Assets-35.86% Debt Debt-to-Equity Ratio10.12 Current Ratio0.61 Quick Ratio0.40 Sales & Book Value Annual Sales$79.96 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book8.60Miscellaneous Outstanding Shares49,954,000Free Float46,307,000Market Cap$64.44 million OptionableOptionable Beta1.36 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:AKYA) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHave you tried Elon Musk’s 70X AI agent?Jeff Brown picked Nvidia in 2016 - it's up 25,155% since. He recommended Bitcoin at $240 - it's up 31,219% sin...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKYA Stock Alerts